V Nagaraja1, G D Eslick. 1. The Whiteley-Martin Research Centre, Discipline of Surgery, The University of Sydney, Nepean Hospital, Penrith, New South Wales, Australia.
Abstract
BACKGROUND: The current recommendation for patients with cutaneous melanoma and a positive sentinel lymph node (SLN) biopsy is a complete lymph node dissection (CLND). However, metastatic melanoma is not present in approximately 80% of CLND specimens. A meta-analysis was performed to identify the clinicopathological variables most predictive of non-sentinel node (NSN) metastases when the sentinel node is positive in patients with melanoma. METHODS: A systematic search was conducted using MEDLINE, PubMed, EMBASE, Current Contents Connect, Cochrane library, Google scholar, Science Direct, and Web of Science. The search identified 54 relevant articles reporting the frequency of NSN metastases in melanoma. Original data was abstracted from each study and used to calculate a pooled odds ratio (OR) and 95% confidence interval (95% CI). FINDINGS: The pooled estimates that were found to be significantly associated with the high likelihood of NSN metastases were: ulceration (OR: 1.88, 95% CI: 1.53-2.31), satellitosis (OR: 3.25, 95% CI: 1.86-5.66), neurotropism (OR: 2.51, 95% CI: 1.39-4.53), >1 positive SLN (OR: 1.77, 95% CI: 1.2-2.62), Starz 3 (old) (OR: 1.83, 95% CI: 0.89-3.76), Angiolymphatic invasion (OR: 2.46, 95% CI: 1.34-4.54), extensive location (OR: 2.22, 95% CI: 1.74-2.81), macrometastases >2 mm (OR: 1.95, 95% CI: 1.61-2.35), extranodal extension (OR: 3.38, 95% CI: 1.79-6.40) and capsular involvement (OR: 3.16, 95% CI: 1.37-7.27). There were 3 characteristics not associated with NSN metastases: subcapsular location (OR: 0.51, 95% CI: 0.38-0.67), Rotterdam Criteria <0.1 mm (OR: 0.29, 95% CI: 0.17-0.50) and Starz I (new) (OR: 0.44, 95% CI: 0.22-0.91). Other variables including gender, Breslow thickness 2-4 mm and extremity as primary site were found to be equivocal. INTERPRETATION: This meta-analysis provides evidence that patients with low SLN tumor burden could probably be spared the morbidity associated with CLND. We identified 9 factors predictive of non-SLN metastases that should be recorded and evaluated routinely in SLN databases. However, further studies are needed to confirm the standard criteria for not performing CLND. Crown
BACKGROUND: The current recommendation for patients with cutaneous melanoma and a positive sentinel lymph node (SLN) biopsy is a complete lymph node dissection (CLND). However, metastatic melanoma is not present in approximately 80% of CLND specimens. A meta-analysis was performed to identify the clinicopathological variables most predictive of non-sentinel node (NSN) metastases when the sentinel node is positive in patients with melanoma. METHODS: A systematic search was conducted using MEDLINE, PubMed, EMBASE, Current Contents Connect, Cochrane library, Google scholar, Science Direct, and Web of Science. The search identified 54 relevant articles reporting the frequency of NSN metastases in melanoma. Original data was abstracted from each study and used to calculate a pooled odds ratio (OR) and 95% confidence interval (95% CI). FINDINGS: The pooled estimates that were found to be significantly associated with the high likelihood of NSN metastases were: ulceration (OR: 1.88, 95% CI: 1.53-2.31), satellitosis (OR: 3.25, 95% CI: 1.86-5.66), neurotropism (OR: 2.51, 95% CI: 1.39-4.53), >1 positive SLN (OR: 1.77, 95% CI: 1.2-2.62), Starz 3 (old) (OR: 1.83, 95% CI: 0.89-3.76), Angiolymphatic invasion (OR: 2.46, 95% CI: 1.34-4.54), extensive location (OR: 2.22, 95% CI: 1.74-2.81), macrometastases >2 mm (OR: 1.95, 95% CI: 1.61-2.35), extranodal extension (OR: 3.38, 95% CI: 1.79-6.40) and capsular involvement (OR: 3.16, 95% CI: 1.37-7.27). There were 3 characteristics not associated with NSN metastases: subcapsular location (OR: 0.51, 95% CI: 0.38-0.67), Rotterdam Criteria <0.1 mm (OR: 0.29, 95% CI: 0.17-0.50) and Starz I (new) (OR: 0.44, 95% CI: 0.22-0.91). Other variables including gender, Breslow thickness 2-4 mm and extremity as primary site were found to be equivocal. INTERPRETATION: This meta-analysis provides evidence that patients with low SLN tumor burden could probably be spared the morbidity associated with CLND. We identified 9 factors predictive of non-SLN metastases that should be recorded and evaluated routinely in SLN databases. However, further studies are needed to confirm the standard criteria for not performing CLND. Crown
Authors: Andrei Rios-Cantu; Ying Lu; Victor Melendez-Elizondo; Michael Chen; Alejandra Gutierrez-Range; Niloofar Fadaki; Suresh Thummala; Carla West-Coffee; James Cleaver; Mohammed Kashani-Sabet; Stanley P L Leong Journal: Clin Exp Metastasis Date: 2017-07-11 Impact factor: 5.150
Authors: Emilia Migliano; Barbara Bellei; Flavio Andrea Govoni; Giovanni Paolino; Caterina Catricalà; Stefania Bucher; Pietro Donati Journal: J Exp Clin Cancer Res Date: 2013-08-01
Authors: Piotr Rutkowski; Konrad Szydłowski; Zbigniew I Nowecki; Maciej Sałamacha; Tomasz Goryń; Beata Mitręga-Korab; Andrzej Pieńkowski; Wirginiusz Dziewirski; Marcin Zdzienicki Journal: World J Surg Oncol Date: 2015-10-13 Impact factor: 2.754
Authors: Daniel Eiger; Daniel Arcuschin de Oliveira; Renato Leão de Oliveira; Murilo Costa Sousa; Mireille Darc Cavalcante Brandão; Renato Santos de Oliveira Filho Journal: An Bras Dermatol Date: 2018 Jul-Aug Impact factor: 1.896
Authors: Fernando De Marco Dos Santos; Felipe Correa da Silva; Julia Pedron; Roque Domingos Furian; Cristina Fortes; Renan Rangel Bonamigo Journal: An Bras Dermatol Date: 2019 Jan-Feb Impact factor: 1.896
Authors: Karolina Richter; Tomasz Stefura; Krzysztof Macheta; Jonasz Tempski; Jakub Kazoń; Magdalena Szeremeta; Paweł Klimont; Marta Kołodziej-Rzepa; Tomasz Wojewoda; Wojciech M Wysocki Journal: J Clin Med Date: 2022-07-04 Impact factor: 4.964
Authors: Amanda A G Nijhuis; Andrew J Spillane; Jonathan R Stretch; Robyn P M Saw; Alexander M Menzies; Roger F Uren; John F Thompson; Omgo E Nieweg Journal: ANZ J Surg Date: 2019-10-30 Impact factor: 1.872